BKYI (BIO-key International) Current Deferred Revenue: $0.65 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKYI BIO-key International Inc BKYI
42 GF Score
Price $3.15
GF Value $2.30
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is BIO-key International Current Deferred Revenue?

BIO-key International BKYI -0.97% 42 Current Deferred Revenue is $0.65 Mil as of Jun. 2026. GuruFocus rates BKYI with a GF Score™ of 42/100 and a GF Value™ of $2.30 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

BIO-key International's current deferred revenue for the quarter that ended in Jun. 2026 was $0.65 Mil.

BIO-key International Current Deferred Revenue Related Terms

BIO-key International Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for BIO-key International's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BIO-key International Current Deferred Revenue Chart

BIO-key International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.46 0.42 0.77 0.57

BIO-key International Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.66 0.57 0.86 0.65
BKYI
42GF Score
BIO-key International Inc BKYI
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.65 Mil mean?
BIO-key International (BKYI) has a Current Deferred Revenue of $0.65 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on BIO-key International and its competitors.
Is BIO-key International's Current Deferred Revenue too high?
BIO-key International's current Current Deferred Revenue is $0.65 Mil. Overall, BIO-key International has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BIO-key International's Current Deferred Revenue compare to IVDA and SUGP?
BIO-key International's Current Deferred Revenue of $0.65 Mil can be compared against companies in the Business Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Business Services company?
A good Current Deferred Revenue depends on the Business Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on BIO-key International and its competitors. BIO-key International's current Current Deferred Revenue is $0.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BIO-key International stock overvalued right now?
Based on GuruFocus' analysis, BIO-key International (BKYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.30, compared to a current price of $3.15 — trading 37% above its estimated fair value. The current Current Deferred Revenue is $0.65 Mil. BIO-key International's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For BIO-key International (BKYI), the current Current Deferred Revenue is $0.65 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BIO-key International (BKYI) Overvalued in 2026?

Based on GuruFocus' analysis, BIO-key International stock appears to be overvalued. The current stock price of $3.15 is trading 37% above its estimated GF Value™ of $2.30. GuruFocus considers BIO-key International to be Significantly Overvalued.

Key valuation signals for BKYI:

  • Current Deferred Revenue: $0.65 Mil
  • GF Value™: $2.30 vs. price of $3.15 (37% above fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the BKYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BIO-key International Business Description

Address 101 Crawfords Corner Road, Suite 4116, Holmdel, NJ, USA, 07753
BIO-key International Inc is a identity and access management (IAM) platform provider enabling secure work-from-anywhere for enterprise, education, and government customers using secure multi-factor authentication (MFA). Its products include PortalGuard and PortalGuard Identity-as-a-Service (IDaaS) enterprise IAM, WEB-key biometric civil and large-scale ID infrastructure, MobileAuth mobile phone authentication application for iOS and Android, and high-quality, low-cost accessory fingerprint scanner and FIDO-compliant hardware to provide a full and complete solution for identity-innovating customers. The company operates as one operating segment. Its solutions are Passwordless Authentication, Secure Roving Employees, Education, Financial Services, Government, Healthcare, Manufacturing, etc.
42GF Score

Get the complete analysis for BKYI

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.15
Price
$2.30
GF Value